GUIDANCE UPDATE TYPE 2 DIABETES AN OVERVIEW OF THE SIGN GUIDELINE ON PHARMACOLOGICAL MANAGEMENT OF GLYCAEMIC CONTROL.
|
|
- Estella Rodgers
- 5 years ago
- Views:
Transcription
1 TYPE 2 DIABETES AN OVERVIEW OF THE SIGN GUIDELINE ON PHARMACOLOGICAL MANAGEMENT OF GLYCAEMIC CONTROL GUIDANCE UPDATE cpd credits Production of this Guidelines supplement has been funded by an educational grant from Napp Pharmaceuticals Limited. The grant included an honorarium for the author. Napp Pharmaceuticals Limited has reviewed the supplement for technical accuracy and to ensure compliance with regulations. Napp Pharmaceuticals Limited has had no input into or editorial control of the content of this article, which resided with the author and Guidelines at all times. See page 8 for full disclaimer. Date of preparation: March
2 A review of SIGN 154: Pharmacological management of glycaemic control in people with type 2 diabetes Professor Gerard McKay, Consultant Physician, Department of Endocrinology, Diabetes and Clinical Pharmacology, Glasgow Royal Infirmary Introduction Historically, the management of hyperglycaemia in type 2 diabetes has been based on lowering glycated haemoglobin (HbA 1c ) as a surrogate marker, with only metformin and pioglitazone having cardiovascular outcome data. For metformin, this was based on a small sub study of the UK Prospective Diabetes Study (UKPDS), 1 and, for pioglitazone, on the improvement in a secondary endpoint in the PROactive study. 2 Following the finding of increased cardiovascular events with rosiglitazone, 3 the regulatory authorities, initially in the USA in and then in Europe in 2012, 5 mandated that all new treatments for the management of hyperglycaemia show no impact on cardiovascular morbidity and mortality. This has led to a number of large studies for newer drugs as part of their clinical development programme. For the most part no impact on cardiovascular morbidity and mortality, at least over the short term, has been shown, and there have been additional secondary benefits on weight loss and reduced incidence of hypoglycaemia. However, four drugs from two classes have now been shown to improve cardiovascular morbidity and mortality and three of these drugs, canagliflozin, empagliflozin, and liraglutide are licensed for use in the UK. 6 9 The most recent NICE guidance (NICE Guideline 28 on Type 2 diabetes in adults: management) was first published in 2015 and does not capture the new cardiovascular evidence, 10 while SIGN 116 on The management of diabetes (2010) is considerably out of date. 11 Given the likelihood of new evidence impacting on clinical practice, a rapid update of the chapter of SIGN 116 on pharmacological management of glycaemic control in people with type 2 diabetes was commissioned and published in late 2017 as a standalone guideline: Pharmacological management of glycaemic control in people with type 2 diabetes (SIGN 154). 12 Methodology The guideline was developed using an adapted version of the standard SIGN guideline development process. Apart from including one meta-analysis that pooled randomised controlled trials (RCTs) already included in the original guideline, section 3 on targets for glycaemic control, was not updated. 12 The rapid review approach for updating the guideline involved appraisal of five sources of evidence: 12 the existing guideline, published as a chapter of SIGN a series of systematic reviews developed by the Agency of Healthcare Research and Quality (AHRQ) NICE Guideline a primary literature search to update these sources up to vember 2016 cardiovascular outcome trials published during the development period of the guideline (up to September 2017). A consultation period was held to further validate the finalised guideline as an evidence-based approach to help practitioners manage glycaemic control in people with type 2 diabetes; this included the publication of an algorithm to guide choice of first, second, and third-line agents (Figure 1). 12 Metformin When compared with placebo or other agents, metformin is an effective blood glucose-lowering therapy. 13 An AHRQ analysis showed that, when used as monotherapy, there was very little variation between the currently available classes of glucose-lowering medication. 12,14 Gastrointestinal side-effects are the most common adverse events associated with metformin therapy. 14 The risk of hypoglycaemia is low, and weight gain is not a feature. 14 The evidence shows that there is no risk of lactic acidosis specifically related to metformin use, 14 but SIGN 154 advises using with caution in patients with moderate renal impairment. 12 There has been no new evidence relating to cardiovascular morbidity and mortality since UKPDS 34, which showed cardiovascular benefit of metformin in overweight patients with type 2 diabetes. 1,12 Metformin should be considered as the first-line oral treatment option for all people with type 2 diabetes. 12 Sulphonylureas Sulphonylureas have been shown to be effective at lowering blood glucose levels. 12,15 Evidence from trials comparing sulphyonylureas with newer agents supports this, although these studies were designed to look at adverse effects, rather than directly comparing HbA 1c reduction. 12 Compared with newer agents, there are higher rates of hypoglycaemia and increased weight gain when using sulphonylureas. 12,15 Sulphonylureas should be used with caution in patients with mild or moderate renal impairment and avoided in people with severe renal impairment. 12 There is no clear evidence to suggest that sulphonylureas are associated with increased cardiovascular morbidity and mortality. 12 Sulphonylureas should be considered as first-line treatment in people with type 2 diabetes who are intolerant of, or who have contraindications to, metformin, or as a secondor third-line add-on treatment. Caution should be used in those at risk of hypoglycaemia e.g. the elderly. 12 Thiazolidinediones Pioglitazone is the only thiazolidinedione (TZD) with marketing authorisation in the UK, and evidence supports its use for lowering blood glucose. 12 Pioglitazone is associated with weight gain, due, at least in part, to fluid retention, and there is also a risk of bladder cancer. 12,16 As a class, TZDs are associated with an increased risk of fractures (in both men and women). 12,17 There is no contraindication to using pioglitazone in renal impairment. 18 The PROactive study showed, as a secondary endpoint, improved cardiovascular outcomes with pioglitazone compared with placebo, 19 but this is at the expense of an increased risk of heart failure. 12,20 Pioglitazone should be considered for dual or triple therapy in the management of type 2 diabetes but should not be used in patients with heart failure. The risk of fracture should be considered with long-term use
3 Figure 1: Algorithm for glucose lowering 12 First line in ADDITION to lifestyle Efficacy CV benefit Hypoglycaemia risk Weight Main adverse events In CKD stage 3a Metformin* Moderate Yes Low Reduction Gastrointestinal Maximum 2 g daily SET GLYCAEMIC TARGET: HbA1C <7% (53 mmol/mol) USUAL APPROACH Second line IF NOT REACHING TARGET AFTER 3 6 MONTHS 2, ADD Sulphonylurea* or SGLT2 inhibitor* or Efficacy Moderate CV benefit Yes (specifi c agents) 3 Hypoglycaemia risk Low Weight Loss Main adverse events Hypoglycaemia Genital mycotic In CKD stage 3a Careful monitoring 1 Do not initiate 4 Third line Efficacy IF NOT REACHING TARGET AFTER 3 6 MONTHS, REVIEW ADHERENCE: Sulphonylurea* or CV benefit Yes (specifi c agents) 3 Hypoglycaemia risk Weight Main adverse events Low Loss Gastrointestinal In CKD stage 3a Dose unchanged 8 Fourth line Or an injectable agent If BMI>30 kg/m 2 GLP-1 agonist* Add either an additional oral SGLT2 inhibitor* or Stop DPP-4 inhibitor Consider reducing sulphonylurea Continue metformin Can continue pioglitazone Can continue SGLT2 inhibitor IF NOT REACHING TARGET AFTER 3 6 MONTHS, REVIEW ADD ADDITIONAL AGENT(S) FROM THIRD-LINE OPTIONS Algorithm summarises evidence from the guideline in the context of the clinical experience of the Guideline Development Group. It does not apply in severe renal or hepatic insuffi ciency. Prescribers should refer to the British National Formulary ( the Scottish Medicines Consortium ( and Medicines and Healthcare products Regulatory Agency (MHRA) warnings for updated guidance on licensed indications, full contraindications, and monitoring requirements. * Continue medication at each stage if EITHER individualised target achieved OR HbA 1c falls more than 0.5% (5.5 mmol/mol) in 3 6 months. Discontinue if evidence that ineffective. OR INDIVIDUALISED AS AGREED ALTERNATIVE APPROACH: if osmotic symptoms or intolerant of metformin Sulphonylurea* The following are also accepted by the SMC for fi rst-line use where metformin and sulphonylureas are not tolerated: canaglifl ozin, dapaglifl ozin or ONCE empaglifl ozin (SGLT2 inhibitors) OSMOTIC linagliptin, sitagliptin, or vildagliptin SYMPTOMS (DPP-4 inhibitors) RESOLVED, pioglitazone (thiazolidinedione) ADD IF SEVERE OSMOTIC SYMPTOMS WITH WEIGHT LOSS OR POSSIBILITY OF Hypoglycaemia TYPE 1 DIABETES (URGENT PHONE Careful monitoring 1 SECONDARY CARE IMMEDIATELY) REVIEW ADHERENCE: THEN GUIDED BY PATIENT PROFILE ONE OF: DPP-4 inhibitor* or Pioglitazone* Low/moderate Moderate Probable (but fl uid retention) Low Low Neutral Few Oedema/fractures 6 Reduce dose 5 Dose unchanged THEN GUIDED BY PATIENT PROFILE 7 agent from a different class DPP-4 inhibitor* or Pioglitazone* Or an injectable agent If BMI<30 kg/m 2 Basal insulin* Inject before bed Use NPH (isophane) insulin or est longer-acting analogues according to risk of hypoglycaemia 10 Can continue metformin, pioglitazone, DPP-4 inhibitor or SGLT2 inhibitor Hypoglycaemia Can reduce or stop sulphonylurea Dose unchanged 9 ADHERENCE: THEN GUIDED BY PATIENT PROFILE (NEED SPECIALIST INPUT) IF INSULIN INTENSIFICATION REQUIRED (NEED SPECIALIST INPUT) ADD PRANDIAL INSULIN OR SWITCH TO TWICE-DAILY MIXED BIPHASIC INSULIN 1 Consider dose reduction; 2 Do not delay if fi rst-line options not tolerated/inappropriate; 3 See full guideline pages 23 and 26-27; 4 See BNF: specifi c agents can be continued at reduced dose; 5 See BNF: no dose reduction required for linagliptin; 6 Pioglitazone is contraindicated in people with (or with a history of) heart failure or bladder cancer, 7 Do not combine dapaglifl ozin with pioglitazone; 8 Caution with exenatide when egfr<50 ml/min/1.73 m 2 ; 9 Adjust according to response; 10 Driving, occupational hazards, risk of falls, previous history. HbA 1c = glycated haemoglobin; CV=cardiovascular; CKD=chronic kidney disease; CKD 3A=chronic kidney disease stage 3A (estimated glomerular fi ltration rate ml/min/1.73 m 2 ); SGLT2=sodium-glucose co-transporter-2; DPP-4=Dipeptidyl peptidase-4; BMI=body mass index. 4 5
4 DPP-4 inhibitors Five dipeptidyl peptidase-4 (DPP-4) inhibitors are currently available in the UK, all have been shown to lower blood glucose, 12 but the effect, at times, is modest. The evidence shows that DPP-4 inhibitors are associated with neither weight gain nor hypoglycaemia. 12 Dose reduction for all DPP-4 inhibitors except linagliptin is required in renal impairment. 12 At the time of developing the guideline, three major cardiovascular outcome studies had been published for alogliptin (EXAMINE), saxagliptin (SAVOR-TIMI 53), and sitagliptin (TECOS), showing no increase in cardiovascular morbidity and mortality compared with placebo or usual care There was, however, an increase in the rate of hospitalisation for heart failure in people treated with saxagliptin compared with placebo. 22 DPP-4 inhibitors should be considered for dual or triple therapy in the management of type 2 diabetes. 12 SGLT2 inhibitors The evidence reviewed supports all sodium glucose co-transporter 2 (SGLT2) inhibitors as having efficacy for lowering blood glucose both as monotherapy and in combination with other glucose-lowering agents. 12 There is, however, no evidence to support the use of SGLT2 inhibitors over metformin for monotherapy. 12 The risk of hypoglycaemia with SGLT2 inhibitors is low and there is evidence to support significant weight loss as a secondary benefit. 12 The most common reported side-effect is genital mycotic infections, and there is also an increased risk of diabetic ketoacidosis. 12 In one trial, canagliflozin was associated with a higher rate of fractures and lower limb amputation compared with placebo. 7 Although the risk of lower limb amputation has not been seen in clinical trials for other agents in this class the European Medicines Agency has recommended that the product information of all SGLT2 inhibitors contains information on the risk of lower limb amputation. 12,24 There is some evidence that canagliflozin is beneficial in early diabetic nephropathy; it should be noted that SGLT2 inhibitors should not be initiated in individuals with chronic kidney disease and in the event of a decrease in estimated glomerular filtration rate, treatment should be adjusted depending on the individual agent. 12 There have been two large cardiovascular outcomes studies in this class: EMPA-REG and CANVAS for empagliflozin and canagliflozin, respectively. 7,8 Both studies recruited patients with type 2 diabetes and a high risk of cardiovascular disease and those who were treated with an SGLT2 inhibitor had improved cardiovascular outcomes compared with placebo. 7,8,12 SGLT2 inhibitors should be considered as add on to metformin in people with type 2 diabetes. In individuals with established cardiovascular disease SGLT2 inhibitors with proven cardiovascular benefit should be considered (empagliflozin or canagliflozin). 12 GLP-1 receptor agonists There is evidence to support the efficacy of all glucagon-like peptide-1 (GLP-1) receptor agonists for lowering blood glucose, mainly as add on to oral therapy, but also in combination with insulin. 12 The main side-effect resulting in discontinuation is gastrointestinal upset, GLP-1 receptor agonists are not associated with severe hypoglycaemia, unless used in combination with other blood glucose-lowering agents that are known to have this effect. 12 Weight loss is a feature of this drug class. 12 dose adjustment is required in mild renal impairment, but advice for use and dose alteration in moderate and severe renal impairment varies between individual drugs. 12 In a study of patients with established cardiovascular disease, once-daily liraglutide showed improved outcomes compared with placebo, 9 while both once daily lixisenatide and once-weekly exenatide have demonstrated cardiovascular non-inferiority compared with placebo (placebo and standard of care). 25,26 Glucagon-like peptide-1 receptor agonist therapy should be considered in people with a body mass index 30kg/m 2 (or ethnicity adjusted equivalent) in combination with oral agents or insulin as thirdor fourth-line treatment. 12 They are an alternative to insulin when oral agents are inadequate and, in those with established cardiovascular disease, GLP-1 receptor agonists with proven cardiovascular benefit, currently liraglutide, should be considered. 12 Insulin All insulin preparations have efficacy in treating hyperglycaemia. When moving from oral to insulin therapy metformin should be continued but consideration should be given to discontinuing other glucose-lowering agents. 12 Insulin is usually started as once-daily NPH insulin, but basal analogues can be considered if there are problems with recurrent hypoglycaemia or when an individual requires assistance with injections. 12 Mixed insulin or prandial insulin are both valid options when intensifying treatment with the aim of optimising glycaemic control while minimising the risk of hypoglycaemia and weight gain. 12 Key points A rapid update of the chapter of SIGN 116 on pharmacological management of glycaemic control in people with type 2 diabetes was commissioned and published in late 2017 as a standalone guideline, SIGN 154 The updated guideline considers the results of cardiovascular outcome trials published during the development period of the guideline Metformin should be considered as the first-line oral treatment option for all people with type 2 diabetes For individuals with established cardiovascular disease, evidence of proven cardiovascular benefit should be considered when choosing SGLT2 inhibitors or GLP-1 receptor agonists. SGLT2=sodium glucose co-transporter 2; GLP-1=glucagon-like peptide-1 Conclusion The updated guideline on the Pharmacological management of glycaemic control in people with type 2 diabetes (SIGN 154) was published in vember The guideline is not intended to be overly prescriptive, but provides information to support the selection of appropriate treatment for individuals, guided by specific patient characteristics and needs. Treatment choice should not exclude basic advice on the need for increased activity or dietary modification the potential to deliver this as part of routine primary care was demonstrated in the recently published DiRECT study. 27 The updated guideline also prompts the prescriber to review treatment efficacy/safety at 3 6 months and to make changes, if necessary. Underpinned by robust evidence and accompanied by an easy-to-follow treatment algorithm that can be used in the delivery of routine clinical care, the updated guideline should help improve the treatment of those with type 2 diabetes. Initial feedback on the guideline and its role in management has been positive. 6 7
5 Conflicts of interest Professor McKay has received an honorarium from Napp Pharmaceuticals Limited for his work on this article and has been paid by many companies for advisory work and presentations relating to the management of type 2 diabetes. Professor McKay was a member of the guideline update group for SIGN 154. References 1. UK Prospective Diabetes Study Group. Lancet 1998; 352 (9131): Dormandy J, Charbonnel B, Eckland D et al. Lancet 2005; 366 (9493): Singh S, Loke Y, Furberg C. JAMA 2007; 298 (10): Food and Drug Administration. Guidance for industry: diabetes mellitus evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. FDA, downloads/drugs/guidances/ucm pdf 5. European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. EMA, www. ema.europa.eu/docs/en_gb/document_library/ Scientific_guideline/2012/06/WC pdf 6. Marso S, Bain S, Consoli A et al. N Engl J Med 2016; 375: Neal B, Perkovic V, Mahaffey K et al. N Engl J Med 2017; 377: Zinman B, Wanner C, Lachin J et al. N Engl J Med 2015; 373: Marso S, Daniels G, Brown-Frandsen K et al. N Engl J Med 2016; 375 (4): NICE. Type 2 diabetes in adults: management. NICE Guideline 28. NICE, 2015 (updated 2017). Available at Scottish Intercollegiate Guidelines Network. SIGN 116: Management of diabetes. SIGN, Scottish Intercollegiate Guidelines Network. SIGN 154: Pharmacological management of glycaemic control in people with type 2 diabetes. SIGN, Saenz A, Fernandez-Esteban I, Mataix A et al. Cochrane Database of Systematic Reviews 2005; 3: CD Bolen S, Wilson L, Vassy J et al. Ann Intern Med 2007; 147 (6): UK Prospective Diabetes Study Group. Lancet 1998; 352 (9131): Li Z, Sun M, Wang F et al. Int J Clin Pharmacol Ther 2017; 55 (3): Colhoun H, Livingstone S, Looker H et al. Diabetologia 2012; 55: Budde K, Neumayer H, Fritsche L et al. Br J Clin Pharmacol 2003; 55 (4): Wilcox R, Bousser M, Betteridge D et al. Stroke 2007; 38: Lago R, Singh P, Nesto R. Lancet 2007; 370 (9593): White W, Cannon C, Heller S et al. N Engl J Med 2013; 369: Scirica B, Bhatt D, Braunwald E et al. N Engl J Med 2013; 369: Green J, Bethel M, Armstrong P et al. N Engl J Med 2015; 373: European Medicines Agency. PRAC assessment report. EMA, en_gb/document_library/referrals_document/ SGLT2_inhibitors_Canagliflozin_20/European_ Commission_final_decision/WC pdf 25. Pfeffer M, Claggett B, Diaz R et al. N Engl J Med 2015; 373 (23): Holman R, Bethel M, Mentz R et al. N Engl J Med 2017; 377: Lean M, Leslie W, Barnes A et al. Lancet 2018; 391 (10120): Production of this supplement has been funded by an educational grant from Napp Pharmaceuticals Limited. The grant included an honorarium for the author. Napp Pharmaceuticals Limited has reviewed the supplement for technical accuracy and to ensure compliance with regulations. Napp Pharmaceuticals Limited has had no input into or editorial control of the content of this article, which resided with the author and Guidelines at all times. The views and opinions in this supplement are not necessarily those of Napp Pharmaceuticals Limited or of Guidelines, its publisher, advisers, or advertisers. Readers are strongly advised to refer to the summary of product characteristics when a guideline describes a drug therapy or when full details and the clinical significance of a product s contraindications, special precautions, drug interactions, adverse reactions, or overdose are required. While every care has been taken to ensure the accuracy of this Guidelines supplement, this does not diminish the requirement to exercise clinical judgement and the publishers cannot accept liability for any errors and omissions. The copyright of Guidelines (including the Guidelines brand, logo, and the design and format of the book) rests with MGP Ltd unless otherwise stated. part of this publication may be reproduced in any form without the permission of the publisher. Date of preparation: March 2018 MGP Ltd
sitagliptin, 25mg, 50mg and 100mg film-coated tablets (Januvia ) SMC No. (1083/15) Merck Sharp and Dohme UK Ltd
sitagliptin, 25mg, 50mg and 100mg film-coated tablets (Januvia ) SMC No. (1083/15) Merck Sharp and Dohme UK Ltd 07 August 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Canagliflozin in combination therapy for Final scope Remit/appraisal objective To appraise the clinical and cost effectiveness
More informationOverview T2DM medications. Winnie Ho
Overview T2DM medications Winnie Ho Diabetes in Australia 1.7 million Australians with diabetes, of these 85% have T2DM 2-fold excess risk CV death in patients with diabetes Risk factor for progression
More informationMANAGEMENT OF TYPE 2 DIABETES
MANAGEMENT OF TYPE 2 DIABETES 3 Month trial of lifestyle changes. Refer to DESMOND structured education programme. Set glycaemic target HbA1c < 7.0% (53mmol/mol) or individualised If HbA1c > 53mmol/mol
More informationHow can we improve outcomes in Type 2 diabetes?
How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management Identify and treat all risk factors Use rational pharmacological therapy
More informationEmpagliflozin (Jardiance ) for the treatment of type 2 diabetes mellitus, the EMPA REG OUTCOME study
Empagliflozin (Jardiance ) for the treatment of type 2 diabetes mellitus, the EMPA REG OUTCOME study POSITION STATEMENT: Clinicians should continue to follow MHRA advice and NICE technology appraisal guidance
More informationSIGN 154 Pharmacological management of glycaemic control in people with type 2 diabetes. A national clinical guideline November 2017.
SIGN 154 Pharmacological management of glycaemic control in people with type 2 diabetes A national clinical guideline November 2017 Evidence KEY TO EVIDENCE STATEMENTS AND RECOMMENDATIONS LEVELS OF EVIDENCE
More informationScottish Medicines Consortium
Scottish Medicines Consortium saxagliptin, 5mg film-coated tablet (Onglyza ) No. (603/10) Bristol-Myers Squibb Pharmaceuticals Ltd 05 February 2010 The Scottish Medicines Consortium (SMC) has completed
More informationScottish Medicines Consortium
Scottish Medicines Consortium liraglutide 6mg/mL prefilled pen for injection (3mL) (Victoza ) Novo Nordisk Ltd. No. (585/09) 06 November 2009 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationempagliflozin 10mg and 25mg tablet (Jardiance ) SMC No. (993/14) Boehringer Ingelheim / Eli Lilly
empagliflozin 10mg and 25mg tablet (Jardiance ) SMC No. (993/14) Boehringer Ingelheim / Eli Lilly 05 September 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationDept of Diabetes Main Desk
Dept of Diabetes Main Desk 01202 448060 Glucose management in Type 2 Diabetes in Adults The natural history of type 2 diabetes is for HbA1c to deteriorate with time. A stepwise approach to treatment is
More informationNational Institute for Health and Care Excellence. Single Technology Appraisal (STA) Empagliflozin combination therapy for treating type 2 diabetes
National Institute for Health and Care Excellence Comment 1: the draft remit Single Technology Appraisal (STA) Empagliflozin combination therapy for treating type 2 diabetes Response to consultee and commentator
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Dapagliflozin in combination therapy for the Final scope Remit/appraisal objective To appraise the clinical and
More informationBristol-Myers Squibb / AstraZeneca ADVICE dapagliflozin (Forxiga ) Indication under review: SMC restriction: Chairman, Scottish Medicines Consortium
Re-Submission dapagliflozin 5mg and 10mg film-coated tablets (Forxiga ) SMC No. (799/12) Bristol-Myers Squibb / AstraZeneca 07 February 2014 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationHEART FAILURE AND DIABETES MELLITUS: DANGEROUS LIASONS MICHEL KOMAJDA, MD
HEART FAILURE AND DIABETES MELLITUS: DANGEROUS LIASONS MICHEL KOMAJDA, MD Author affiliations: Department of Cardiology, Hôpital Saint Joseph, Paris, France Address for correspondence: Michel Komajda,
More informationCOMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date)
Drug, Treatment, Device name ( Vipidia; Takeda) COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date) Licensed indication To improve glycaemic control in
More informationOral Treatments for Type 2 Diabetes. Prescribing Support Pharmacist
Oral Treatments for Type 2 Diabetes Prescribing Support Pharmacist Learning Outcomes Familiar with classes of oral hypoglycaemic agents (OHAs) used in controlling blood glucose levels When to use each
More information667FM.5.1 MANAGEMENT OF TYPE 2 DIABETES: BLOOD-GLUCOSE-LOWERING THERAPY
667FM.5.1 MANAGEMENT OF TYPE 2 DIABETES: BLOOD-GLUCOSE-LOWERING THERAPY Contents Introduction... 1 Patient Education for People with Type 2 Diabetes... 2 Dietary Advice for People with Type 2 Diabetes...
More informationThere have been important changes in diabetes care which may not be covered in undergraduate textbooks.
Diabetes Clinical update There have been important changes in diabetes care which may not be covered in undergraduate textbooks. Changes in the diagnosis of diabetes a) HbA1C Since 2011, World Health Organisation
More informationTechnology appraisal guidance Published: 23 November 2016 nice.org.uk/guidance/ta418
Dapagliflozin in triple therapy for treating type 2 diabetes Technology appraisal guidance Published: 23 November 2016 nice.org.uk/guidance/ta418 NICE 2018. All rights reserved. Subject to Notice of rights
More informationCurrent principles of diabetes management
Current principles of diabetes management Prof. Martin Haluzík, MD, DSc. 3 Department of Medicine, General University Hospital and 1st Faculty of Medicine, Charles University in Prague, Czech Republic
More informationCANVAS Program Independent commentary
CANVAS Program Independent commentary Cliff Bailey Aston University, Birmingham, UK 2017 Disclosures and disclaimers Clifford J Bailey CJB has attended advisory boards, undertaken ad hoc consultancy, received
More informationSTEP 3: Add or Substitute with one of
Prescribing of Hypoglycaemic Agents for Adult Patients with Type 2 Diabetes: Sunderland Refer to DESMOND Structured Education classes to promote Increased Physical Activity, Weight Loss and Calories Reduction
More informationGlucose Control drug treatments
Glucose Control drug treatments It should be noted that glitazones are under suspicion of precipitating acute cardiac events and current recommendations contraindicate the use of glitazones in patients
More informationTREATMENTS FOR TYPE 2 DIABETES. Susan Henry Diabetes Specialist Nurse
TREATMENTS FOR TYPE 2 DIABETES Susan Henry Diabetes Specialist Nurse How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management
More informationSodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol
Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has
More informationOral Treatments. SaminaAli Prescribing Support Pharmacist
Oral Treatments for Type 2 Diabetes SaminaAli Prescribing Support Pharmacist Learning Outcomes National Guidance Familiar with classes of oral hypoglycaemic agents (OHAs) used in controlling blood glucose
More informationType 2 Diabetes. Stopping Smoking. Consider referral to smoking cessation. Consider referring for weight management advice.
Type 2 Diabetes Stopping Smoking Consider referral to smoking cessation BMI > 25 kg m² Set a weight loss target of a 5-10% reduction Consider referring for weight management advice Control BP to
More informationOral Pharmacologic Treatment of Type 2 Diabetes Mellitus
Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus You should be offering psychosocial care to all patients with diabetes, says the ADA. Here are the specific recommendations. Summary Recommendation
More informationGLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
GLP-1 agonists Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What do GLP-1 agonists do? Physiology of postprandial glucose regulation Meal ❶ ❷ Insulin Rising plasma
More informationLiraglutide (Victoza) in combination with basal insulin for type 2 diabetes
Liraglutide (Victoza) in combination with basal insulin for type 2 diabetes May 2011 This technology summary is based on information available at the time of research and a limited literature search. It
More informationGuideline for antihyperglycaemic therapy in adults with type 2 diabetes
Guideline for antihyperglycaemic therapy in adults with type 2 diabetes Version Control Version Number Date Amendments made 1 January 2018 1.1 February 2018 Amended to reflect updated SPC advice for sitagliptin
More informationArrange 3 Monthly Review Re-enforce LIFESTYLE advice and check DRUG COMPLIANCE at each visit Target HbA1c < 53mmol/mol
Prescribing of Hypoglycaemic Agents for Adult Patients with Type 2 Diabetes: Sunderland Refer to DESMOND Structured Education classes to promote Increased Physical Activity, Weight Loss and Calories Reduction
More informationManagement of Type 2 Diabetes Cardiovascular Outcomes Trials Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas
Management of Type 2 Diabetes Cardiovascular Outcomes Trials 2018 Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas Speaker Disclosure Dr. Blevins has disclosed that he has received grant support
More informationdulaglutide 0.75mg and 1.5mg solution for injection in pre-filled pen (Trulicity ) SMC No. (1110/15) Eli Lilly and Company Ltd.
dulaglutide 0.75mg and 1.5mg solution for injection in pre-filled pen (Trulicity ) SMC No. (1110/15) Eli Lilly and Company Ltd. 04 December 2015 The Scottish Medicines Consortium (SMC) has completed its
More informationNavigating the New Options for the Management of Type 2 Diabetes
Navigating the New Options for the Management of Type 2 Diabetes Clinical Associate Professor Mark Kennedy Department of General Practice, University of Melbourne Chair, Primary Care Diabetes Society of
More informationOral Agents. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
Oral Agents Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What would your ideal diabetes drug do? Effective in lowering HbA1c No hypoglycaemia No effect on weight/ weight
More informationDipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol
Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationDPP-4/SGLT2 inhibitor combined therapy for type 2 diabetes
THERAPY REVIEW DPP-4/SGLT2 inhibitor combined therapy for type 2 diabetes STEVE CHAPLIN SPL DPP-4 inhibitors and SGLT2 inhibitors lower blood glucose by complementary mechanisms of action, and two fixeddose
More informationNewer Diabetes Treatments Drug Class Update with New Drug Evaluation: Semaglutide and Ertugliflozin
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationinsulin degludec/liraglutide 100 units/ml / 3.6mg/mL solution for injection pre-filled pen (Xultophy ) SMC No. (1088/15) Novo Nordisk A/S
insulin degludec/liraglutide 100 units/ml / 3.6mg/mL solution for injection pre-filled pen (Xultophy ) SMC No. (1088/15) Novo Nordisk A/S 4 September 2015 The Scottish Medicines Consortium (SMC) has completed
More informationUpdate on Diabetes Cardiovascular Outcome Trials
Update on Diabetes Cardiovascular Outcome Trials Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationexenatide 2mg powder and solvent for prolonged-release suspension for injection (Bydureon ) SMC No. (748/11) Eli Lilly and Company Limited
exenatide 2mg powder and solvent for prolonged-release suspension for injection (Bydureon ) SMC No. (748/11) Eli Lilly and Company Limited 09 December 2011 The Scottish Medicines Consortium (SMC) has completed
More informationthe person is intolerant of either metformin or a sulphonylurea, or treatment with metformin or a sulphonylurea is contraindicated, and
Exenatide (Byetta) and Liraglutide (Victoza) prescribing guidance: Notes for initiation in primary care These incretin mimetics are given by subcutaneous injection once or twice daily. They have similar
More informationdapagliflozin 5mg and 10mg film-coated tablets (Forxiga ) SMC No. (799/12) Bristol-Myers Squibb / AstraZeneca
dapagliflozin 5mg and 10mg film-coated tablets (Forxiga ) SMC No. (799/12) Bristol-Myers Squibb / AstraZeneca 07 September 2012 (Issued 07 December 2012) The Scottish Medicines Consortium (SMC) has completed
More informationMedical therapy advances London/Manchester RCP February/June 2016
Medical therapy advances London/Manchester RCP February/June 2016 Advances in medical therapies for diabetes mellitus Duality of interest: The speaker or institutions with which he is associated has received
More informationMedicines Optimisation Team Standard Operating procedure for Alogliptin Audit:
Medicines Optimisation Team Standard Operating procedure for Alogliptin Audit: To review type 2 diabetic patients prescribed dipedtidylpeptidase-4 (DPP-4) inhibitors (linagliptin (Trajenta, saxagliptin
More informationHave you seen a patient like Carol *?
(linagliptin) 5mg tablets Have you seen a patient like Carol *? *Hypothetical patient profile Carol * : 70 years old Retired schoolteacher *Hypothetical patient profile CAROL*: T2D patient with moderate
More informationSGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: SGLT2 Inhibitors Page: 1 of 7 Last Review Date: June 22, 2018 SGLT2 Inhibitors Description Invokana
More informationManagement of Type 2 Diabetes
Management of Type 2 Diabetes Pathophysiology Insulin resistance and relative insulin deficiency/ defective secretion Not immune mediated No evidence of β cell destruction Increased risk with age, obesity
More informationHave you seen a patient like Elaine *?
(linagliptin) 5mg tablets Have you seen a patient like Elaine *? *Hypothetical patient profile Elaine * : 60 years old Housewife *Hypothetical patient profile ELAINE*: T2D Patient with early signs of kidney
More informationNational Horizon Scanning Centre. Saxagliptin (BMS ) for type 2 diabetes. April 2008
Saxagliptin (BMS 477118) for type 2 diabetes This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement
More informationManagement of Type 2 Diabetes Mellitus. Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism
Management of Type 2 Diabetes Mellitus Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism Disclosures Working for Intermountain Healthcare Some of the views represented are the opinion of ABIM-certified
More informationThe Death of Sulfonylureas? A Review of New Diabetes Medications
The Death of Sulfonylureas? A Review of New Diabetes Medications Kelly Hoenig, Pharm.D., BCPS Cedar Rapids Family Medicine Residency 2/4/17 Objectives Review GLP-1 Agonists, DPP-IV Inhibitors and SGLT-2
More informationCardiovascular outcome studies with glucagon-like peptide 1 receptor agonists what will REWIND add?
Editorial Page 1 of 5 Cardiovascular outcome studies with glucagon-like peptide 1 receptor agonists what will REWIND add? Keith C. Ferdinand, Indrajeet Mahata Department of Medicine, Tulane School of Medicine,
More informationCase Studies in Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials
Case Studies in Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials Louis Kuritzky MD Clinical Assistant Professor Emeritus Department of Community Health and Family Medicine College of Medicine
More informationSafety profile of Liraglutide: Recent Updates. Mohammadreza Rostamzadeh,M.D.
Safety profile of Liraglutide: Recent Updates Mohammadreza Rostamzadeh,M.D. Pancreatitis: Victoza post-marketing experience: spontaneous reports of pancreatitis For the majority of the cases, there is
More informationCan We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists
Can We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists Robert R. Henry, MD Professor of Medicine University of California, San Diego Relevant Conflict
More informationNew Medicine Assessment
New Medicine Assessment Insulin degludec plus liraglutide (Xultophy ) 100 units/ml insulin degludec plus 3.6 mg/ml liraglutide solution for injection in a pre-filled pen Treatment of adults with type 2
More information01/09/2017. Outline. SGLT 2 inhibitor? Diabetes Patients: Complex and Heterogeneous. Association between diabetes and cardiovascular events
MICROVASCULAR COMPLICATIONS Incidence of outcome g 1 Cardioprotective Effects of SGLT2s Relevant for Which T2 Diabetes Patient? SGLT 2 inhibitor? 58 year old, waist circumference 5 cm, PMH: IHD On statin,
More informationCardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes
Biomarkers 2018 Cardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationDrug Class Monograph
Drug Class Monograph Class: Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drugs: Farxiga (dapagliflozin), Invokamet (canagliflozin/metformin), Invokana (canagliflozin), Jardiance (empagliflozin),
More informationProfessor Rudy Bilous James Cook University Hospital
Professor Rudy Bilous James Cook University Hospital Rate per 100 patient years Rate per 100 patient years 16 Risk of retinopathy progression 16 Risk of developing microalbuminuria 12 12 8 8 4 0 0 5 6
More informationDrug Class Update with New Drug Evaluation: Non-insulin Diabetes Treatments (SGLT-2 Inhibitors and GLP-1 Receptor Agonists)
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationThe first stop for professional medicines advice
London Medicines Evaluation Network Overview: Glucagon-Like Peptide-1 receptor analogues The first stop for professional medicines advice 1 London Medicines Evaluation Network Overview: Glucagon-Like Peptide-1
More informationOLD AND NEW DRUGS FOR CONTROLING DIABETES THERAPEUTIC CLASSES AND MECHANISM OF ACTION
OLD AND NEW DRUGS FOR CONTROLING DIABETES THERAPEUTIC CLASSES AND MECHANISM OF ACTION Biljana Parapid, MD, PhD, FESC Belgrade University School of Medicine, Belgrade (Serbia) @biljana_parapid COI International
More informationNew Treatments for Type 2 diabetes. Nandini Seevaratnam April 2016 Rushcliffe Patient Forum
New Treatments for Type 2 diabetes Nandini Seevaratnam April 2016 Rushcliffe Patient Forum Overview Growing population of Type 2 diabetes Basic science on what goes wrong Current treatments Why there is
More informationOver 90% of people with type 2
Article The new class war: SGLT2 inhibitors versus DPP-4 inhibitors Merlin Thomas Over 90% of people with type 2 diabetes will need more than metformin monotherapy to achieve their targets for optimal
More informationUpdate on Cardiovascular Outcome Trials in Diabetes. Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013
Update on Cardiovascular Outcome Trials in Diabetes Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013 Residual Vascular Risk in People with Diabetes 2 Analyses based on 530,083 participants
More informationSGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: SGLT2 Inhibitors Page: 1 of 7 Last Review Date: November 30, 2018 SGLT2 Inhibitors Description
More informationCanagliflozin in combination therapy for treating type 2 diabetes
Canagliflozin in combination therapy for treating type 2 Issued: June 2014 guidance.nice.org.uk/ta NICE has accredited the process used by the Centre for Health Technology Evaluation at NICE to produce
More informationCardiovascular outcome trials in diabetes: what have we learnt?
Diabetes Cardiovascular outcome trials in diabetes: what have we learnt? Mike Kirby, GP and Visiting Professor, The University of Hertfordshire and The Prostate Centre, London; Nick Boon, Honorary Reader,
More informationPLEASE CHECK FULL SPECIFIC PRODUCT CHARACTERISTICS FOR MORE DETAILED AND CURRENT INFORMATION:
Metformin Standard tablets Modified-release tablets Metformin 1g sachets Metformin liquid 500mg/5ml (avoid use as expensive) < 2.00 5.32 for 56 tabs 500mg 13.16 for 60 sachets > 120 Ketoacidosis General
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) Bulletin Glucagon-like peptide 1 (GLP-1) receptor agonist review
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) February 2017 Review February 2020 Bulletin 245 - Glucagon-like peptide 1 (GLP-1) receptor agonist review JPC Recommendations:- Place in therapy
More informationSummary of the risk management plan (RMP) for Synjardy (empagliflozin / metformin)
EMA/217413/2015 Summary of the risk management plan (RMP) for Synjardy (empagliflozin / metformin) This is a summary of the risk management plan (RMP) for Synjardy, which details the measures to be taken
More informationGuidelines to assist General Practitioners in the Management of Type 2 Diabetes. April 2010
Guidelines to assist General Practitioners in the Management of Type 2 Diabetes April 2010 Foreword The guidelines were devised by the Diabetes Day Centre in Beaumont Hospital in consultation with a number
More informationUpdate on Pharmacological Management in Type 2 Diabetes
Update on Pharmacological Management in Type 2 Diabetes Prof. Lotfy Hamed Abo Dahab Professor Of Internal Medicine and Cardiology Vice President of Sohag University ١ My AGENDA Targets For Glycaemic Control
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationAlia Gilani Health Inequalities Pharmacist
Alia Gilani Health Inequalities Pharmacist THE SOUTH ASIAN HEALTH FOUNDATION (U.K.) (Registered Charity No. 1073178) 1. Case Study 2. Factors influencing prescribing 3. Special Considerations 4. Prescribing
More informationEFFECTIVE SHARE CARE AGREEMENT. FOR THE off license use of GLP1 mimetics in combination with insulin IN DUDLEY
Specialist details Patient identifier Name Tel: EFFECTIVE SHARE CARE AGREEMENT FOR THE off license use of GLP1 mimetics in combination with insulin IN DUDLEY The aim of Effective Shared Care Guidelines
More informationTop HF Trials to Impact Your Practice
Top HF Trials to Impact Your Practice Biykem Bozkurt, MD, FACC The Mary and Gordon Cain Chair & Professor of Medicine Medical Care Line Executive, DeBakey VA Medical Center, Director, Winters Center for
More informationTechnology appraisal guidance Published: 27 March 2019 nice.org.uk/guidance/ta572
Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes Technology appraisal guidance Published: 27 March 2019 nice.org.uk/guidance/ta572 NICE 2019. All rights reserved. Subject to
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationPharmacology Update for the Adult Patient - Newer Oral Medications for Diabetes
Pharmacology Update for the Adult Patient - Newer Oral Medications for Diabetes Brooke Hudspeth, PharmD, CDE, MLDE Director of Diabetes Prevention, Kroger Pharmacy Adjunct Assistant Professor, University
More informationTechnology appraisal guidance Published: 26 June 2013 nice.org.uk/guidance/ta288
Dapagliflozin in combination therapy for treating type 2 diabetes Technology appraisal guidance Published: 26 June 2013 nice.org.uk/guidance/ta288 NICE 2018. All rights reserved. Subject to Notice of rights
More informationIncretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors Timothy Bailey, MD, FACE, CPI Director, AMCR Institute,
More informationHelp the Heart. An Update on GLP-1 Agonists and SGLT2 Inhibitors. Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire
Help the Heart An Update on GLP-1 Agonists and SGLT2 Inhibitors Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire Mayo Clinic Grand Rounds May 16, 2017 2017 MFMER slide-1
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationDiabetes, Type 2 Management
CLINICAL GUIDELINE Diabetes, Type 2 Management A guideline is intended to assist healthcare professionals in the choice of disease-specific treatments. Clinical judgement should be exercised on the applicability
More informationYOU HAVE DIABETES. Angie O Connor Community Diabetes Nurse Specialist 25th September 2013
YOU HAVE DIABETES Angie O Connor Community Diabetes Nurse Specialist 25th September 2013 Predicated 2015 figures are already met 1 in 20 have diabetes:1in8 over 60years old Definite Diagnosis is key Early
More informationClass Update: Sodium glucose Cotransporter 2 (SGLT2) Inhibitors
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationNo Increased Cardiovascular Risk for Lixisenatide in ELIXA
ON ISSUES IN THE MANAGEMENT OF TYPE 2 DIABETES JUNE 2015 Coverage of data from ADA 2015, June 5 9 in Boston, Massachusetts No Increased Cardiovascular Risk for Lixisenatide in ELIXA First Cardiovascular
More informationOral and Injectable Non-insulin Antihyperglycemic Agents
Appendix 5: Diabetes Education and Medical Management in Adults with Diabetes Oral and Injectable Non-insulin s This directive will be implemented by RPhs, RNs or RDs who have been deemed authorized implementers.
More informationDIABETES DEBATE - IS NEW BETTER?
DIABETES DEBATE - IS NEW BETTER? WHAT MEDICATION CLASS AFTER METFORMIN TO CONTROL BLOOD SUGAR Dr. Lydia Hatcher, MD, CCFP, FCFP, CHE, D-CAPM Associate Clinical Professor of Family Medicine, McMaster Chief
More informationPharmacological Glycaemic Control in Type 2 Diabetes
Pharmacological Glycaemic Control in Type 2 Diabetes Aim(s) and Objective(s) This guideline aims to offer advice on the pharmacological management for those who require measures beyond diet and exercise
More informationGLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy
More informationWhat s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital
What s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital Therapy considerations in T2DM Thiazoledinediones DPP IV inhibitors GLP 1 agonists Insulin Type Delivery Horizon scanning
More informationLATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines?
LATE BREAKING STUDIES IN DM AND CAD Will this change the guidelines? Objectives 1. Discuss current guidelines for prevention of CHD in diabetes. 2. Discuss the FDA Guidance for Industry regarding evaluating
More informationIMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS
IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS Dr Bidhu Mohapatra, MBBS, MD, FRACP Consultant Physician Endocrinology and General Medicine Introduction 382 million people affected by diabetes
More informationGlucose Control: non-insulin therapies*
South frican Family Practice 2018; 60(1):4-14 Open ccess article distributed under the terms of the reative ommons License [ Y-N-ND 4.0] http://creativecommons.org/licenses/by-nc-nd/4.0 S fr Fam Pract
More information